Pacira Biosciences

Historical price data

Pacira BioSciences is a publicly traded company on a mission to transform pain management by delivering innovative, non-opioid therapies. For over a decade, it has been a leader in the field, commercializing best-in-class products like EXPAREL® and ZILRETTA® while actively advocating for policy changes to expand patient access to non-opioid options. The company's strategic direction focuses on expanding its commercial portfolio, advancing a pipeline that includes a novel gene therapy, and addressing the significant unmet needs in musculoskeletal and postsurgical pain.

Pacira's core technology includes the DepoFoam® multivesicular liposomal platform for sustained drug release, used in EXPAREL®, and the iovera® cryoneurolysis system. The company is also exploring novel modalities like gene therapy for chronic pain.

1 drug in pipeline

Total raised: $64M

Pacira competes with providers of other long-acting local anesthetics, intra-articular injections, neuromodulation devices, and systemic pain medications. Its primary differentiation is its focused portfolio of long-acting, localized, non-opioid therapies, a dedicated commercial and advocacy infrastructure, and its pioneering work in novel modalities like gene therapy for pain.